Artiva Biotherapeutics (ARTV) vs Enanta Pharmaceuticals (ENTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, gaining 141.4% versus a gain of 11.6%. Enanta Pharmaceuticals is the larger company by market cap ($348.9 million vs $326.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | ENTA |
|---|---|---|
| Share price | $6.67 | $11.98 |
| Market cap | $326.10M | $348.92M |
| 1-day change | -4.71% | -3.15% |
| YTD return | +63.17% | -21.56% |
| 1-year return | +141.38% | +11.64% |
| 5-year return | — | -82.69% |
| EPS (TTM) | $-3.23 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.53 | $17.15 |
| 52-week low | $2.71 | $10.20 |
| Distance from 52-week high | -54.09% | -30.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +436.73% | +82.22% |
| Average volume | 402.33K | 226.58K |
| Shares outstanding | 48.89M | 29.13M |
| Employees | 115 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARTV has outperformed ENTA by 129.7 percentage points over the past year.
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 115 employees
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
ARTV vs ENTA FAQ
Which is bigger, Artiva Biotherapeutics or Enanta Pharmaceuticals?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $348.92M compared with $326.10M for Artiva Biotherapeutics (ARTV).
Which stock has performed better over the past year, ARTV or ENTA?
ARTV returned +141.38% over the past 12 months, compared with +11.64% for ENTA (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and Enanta Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Artiva Biotherapeutics and Biotechnology: Pharmaceutical Preparations for Enanta Pharmaceuticals.